重庆博腾制药科技股份有限公司 独立董事 2024 年度述职报告 （曹国华） 各位股东及股东代表： 本人作为重庆博腾制药科技股份有限公司（以下简称"公司"）的独立董事， 2024 年度，严格按照《中华人民共和国公司法》《上市公司独立董事管理办法》 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等 相关法律法规、规范性文件以及公司《公司章程》《独立董事工作制度》等规定 和要求，诚实、勤勉、独立的履行职责，积极出席公司召开的相关会议，及时了 解公司的生产经营信息，全面关注公司的发展状况，认真审议各项议案，充分发 挥独立董事的独立性和专业性作用，切实维护公司和股东的合法利益，为公司的 长远发展献言献策。 现将 2024 年度本人履职情况报告如下： 一、 本人基本情况 本人曹国华，博士。现任公司独立董事，重庆大学经济与工商管理学院教授、 博士生导师，重庆安诚保险股份有限公司独立董事，重庆机电控股集团信博投资 管理有限公司董事。 本人未在公司担任除独立董事外的其他职务，与公司及控股股东、实际控制 人不存在直接或间接利害关系，或其他可能妨碍本人进行独立客观判断的关系。 经自查，本人满足独立董事的任 ...

（二零二五年三月） | 第一章 | 总则 2 | | --- | --- | | 第二章 | 经营宗旨和范围 3 | | 第三章 | 股份 3 | | 第一节 | 股份发行 3 | | 第二节 | 股份增减和回购 4 | | 第三节 | 股份转让 5 | | 第四章 | 股东和股东会 6 | | 第一节 | 股东 6 | | 第二节 | 股东会的一般规定 8 | | 第三节 | 股东会的召集 12 | | 第四节 | 股东会的提案与通知 13 | | 第五节 | 股东会的召开 15 | | 第六节 | 股东会的表决和决议 17 | | 第五章 | 董事会 22 | | 第一节 | 董事 22 | | 第二节 | 董事会 26 | | 第三节 | 董事会秘书 30 | | 第六章 | 总经理及其他高级管理人员 31 | | 第七章 | 监事会 33 | | 第一节 | 监事 33 | | 第二节 | 监事会 34 | | 第八章 | 财务会计制度、利润分配和审计 35 | | 第一节 | 财务会计制度 35 | | 第二节 | 内部审计 40 | | 第三节 | 会计师事务所的聘任 40 | | 第九章 | 通 ...

Financial Performance - The company reported a loss during the reporting period, primarily due to underutilization of production capacity, leading to increased fixed costs and a decrease in overall gross margin [14]. - The company reported a revenue of RMB 1.2 billion for the fiscal year 2024, representing a year-over-year growth of 15% [28]. - The company's operating revenue for 2024 was ¥3,011,966,354.32, a decrease of 17.87% compared to ¥3,667,417,122.49 in 2023 [33]. - The net profit attributable to shareholders for 2024 was -¥287,753,297.39, representing a decline of 207.83% from ¥266,859,527.37 in 2023 [33]. - The net cash flow from operating activities decreased by 35.53% to ¥405,525,823.67 in 2024, down from ¥629,056,261.15 in 2023 [33]. - The overall gross margin for the company was approximately 25%, a decline of 16 percentage points year-on-year, with overseas market gross margin at about 36% and domestic market gross margin at -8% [62]. - The company reported a net loss from non-operating income of -¥15,604,028.89 in 2024, compared to a gain of ¥18,866,254.68 in 2023 [38]. - The company reported a total revenue of 268.3 million in the latest quarter, showing a significant increase compared to the previous period [127]. Client and Market Expansion - The company has a global workforce of over 4,200 employees and has served more than 1,200 clients worldwide, with 185 new clients added during the period [11]. - The company’s overseas business revenue accounted for approximately 74% of its main business income during the reporting period [20]. - User data indicates an increase in active clients by 20%, reaching a total of 500,000 users [28]. - The company is expanding its market presence in Europe, targeting a 10% market share by the end of 2025 [28]. - The company has established 18 operational sites across China, the US, and Europe, employing 1,213 R&D personnel, with 1,062 in China, 123 in the US, and 28 in Europe [52]. - The company has established a strong collaboration with over 1,000 clients, including major global pharmaceutical companies, enhancing its competitive edge in the CDMO industry [59]. Research and Development - The company is focused on expanding its capabilities in small molecule formulations, gene cell therapy, and new molecular fields [20]. - The company plans to increase its R&D expenditure by 30% in the upcoming year to support innovation [28]. - The company has invested RMB 100 million in new technology development for gene therapy, aiming to advance its product pipeline [28]. - The company completed 216 quality audits during the reporting period, including 22 official regulatory audits, with its Chongqing factory passing the US FDA inspection with "zero defects" [56]. - The company’s small molecule API business accounted for approximately 91% of revenue, a year-on-year decrease of about 21%, while other new businesses (small molecule formulation, gene and cell therapy, new molecular business) saw a revenue share of about 8%, with a year-on-year growth of approximately 35% [49]. Operational Efficiency and Cost Management - The gross margin improved to 45%, up from 40% in the previous year, due to operational efficiencies [28]. - The company is focused on enhancing its compliance capabilities to gain a competitive edge in the restructuring of global supply chains [48]. - The company’s operational efficiency improved, with overall expenses decreasing by about 20% [62]. - The company aims to restore revenue growth and gradually achieve profitability as a key operational goal [111]. - The company plans to enhance CRM marketing transformation to achieve breakthroughs in both quality and quantity of business expansion [111]. Environmental, Health, and Safety (EHS) - The company has established a comprehensive EHS (Environment, Health, and Safety) system, which is considered a core competitive advantage [19]. - The management highlighted a commitment to sustainability, with initiatives aimed at reducing carbon emissions by 20% by 2025 [28]. - The company is committed to maintaining compliance with local and national environmental standards, ensuring sustainable operational practices [161]. - The company has implemented strict monitoring of various pollutants, including ammonia nitrogen with a discharge limit of 45 mg/L, and has reported no exceedance [162]. - The company has established a comprehensive environmental management plan in place to address potential pollution issues across its facilities [161]. Governance and Shareholder Engagement - The company has a governance structure that complies with relevant laws and regulations, ensuring effective management and oversight [120]. - The board of directors consists of 9 members with diverse professional backgrounds, promoting sound decision-making [120]. - The company is focused on maintaining shareholder engagement through regular meetings and updates [124]. - The company has a structured governance framework in place to address shareholder rights and interests [125]. - The company reported a total remuneration of 14.44 million yuan for directors, supervisors, and senior management in 2024 [137]. Investment and Fundraising - The company reported a total investment of 1,154.9 million yuan in the medical manufacturing base, with a cumulative actual investment of 354.01 million yuan by the end of the reporting period [96]. - The company has committed to using the raised funds for specific projects, with a total of 146,200 million yuan allocated [102]. - The company plans to repurpose unutilized fundraising for permanent working capital, following significant changes in the feasibility of the original fundraising projects [104]. - The company has completed the closure of the fundraising account for the terminated "New Drug Service Outsourcing Base R&D Center Construction Project (Phase II)" [104]. Employee Management and Development - The total number of employees at the end of the reporting period is 4,214, with 1,880 in the parent company and 2,334 in major subsidiaries [145]. - The professional composition includes 2,355 production personnel, 184 sales personnel, 1,213 technical personnel, 48 financial personnel, and 414 administrative personnel [145]. - The employee training program focuses on talent identification, development, and alignment with the company's strategic goals, providing targeted training for different levels and positions [147]. - The company has implemented a dual-channel career development system to support employee growth and organizational capability enhancement [147]. - The company emphasizes a fair and competitive compensation system to attract and retain talent, linking compensation to individual performance and company objectives [149]. Compliance and Internal Control - The company has maintained effective internal control over financial reporting as of December 31, 2024, according to the internal control audit report [158]. - The internal control self-evaluation report indicates that 100% of the total assets and operating income of the evaluated units are included in the company's consolidated financial statements [156]. - The company has established a comprehensive internal control system to continuously improve its internal control level [155]. - The internal control audit report aligns with the board's self-evaluation report, confirming consistency in findings [159]. - The company has implemented compliance training for all employees to enhance overall compliance awareness [155].

股票代码：300363 股票简称：博腾股份 公告编号：2025-006 号 重庆博腾制药科技股份有限公司 关于 2023 年员工持股计划锁定期届满的提示性公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）于 2023 年 10 月 16 日 召开第五届董事会第二十次临时会议及第五届监事会第十五次临时会议，于 2023 年 11 月 1 日召开 2023 年第四次临时股东大会，审议通过《关于公司<2023 年员工持股计划（草案）>及其摘要的议案》《关于公司<2023 年员工持股计划管 理办法>的议案》《关于提请股东大会授权董事会办理公司 2023 年员工持股计划 相关事宜的议案》，同意公司实施 2023 年员工持股计划（以下简称"本持股计 划"）并授权董事会办理相关事宜。2024 年 2 月 27 日，公司完成本持股计划股 票购买。具体内容详见公司分别于 2023 年 10 月 17 日、2023 年 11 月 1 日、2024 年 2 月 27 日在巨潮资讯网（www.cninfo.com.cn）披露的相关公告 ...

股票代码：300363 股票简称：博腾股份 公告编号：2025-003 号 会议召开符合《公司法》及《公司章程》的规定，所作决议合法有效。 一、 会议审议情况 会议在保证所有董事充分发表意见的前提下，以投票表决方式通过以下议案： 1、审议通过《关于拟投资松禾资本细胞与基因产业基金的议案》； 同意公司以自有资金认缴出资不超过 5,000 万元人民币参与投资由深圳市松 禾资本管理有限公司管理的深圳市松禾细胞与基因产业私募股权投资基金（有限 合 伙 ）， 作 为 有 限 合 伙 人 。 具 体 内 容 详 见 公 司 同 日 于 巨 潮 资 讯 网 （www.cninfo.com.cn）发布的《关于参与认购投资基金份额的公告》（公告编号： 2025-004 号）。 重庆博腾制药科技股份有限公司 第五届董事会第三十次临时会议决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）第五届董事会第三十 次临时会议于 2025 年 2 月 26 日（星期三）以通讯会议方式召开，会议通知已于 2025 年 2 月 18 日通过电 ...

股票代码：300363 股票简称：博腾股份 公告编号：2025-004 号 重庆博腾制药科技股份有限公司 关于参与认购投资基金份额的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概述 根据重庆博腾制药科技股份有限公司（以下简称"公司"）现有业务发展情 况，结合公司的战略目标，助力公司新业务发展，公司拟以自有资金认缴出资不 超过 5,000 万元人民币参与投资由深圳市松禾资本管理有限公司（以下简称"松 禾资本"）管理的深圳市松禾细胞与基因产业私募股权投资基金（有限合伙）（以 下简称"基金"或"本合伙企业"），作为有限合伙人，基金规模 15 亿人民币。 公司已于 2025 年 2 月 26 日召开第五届董事会第三十次临时会议，审议通过 《关于拟投资松禾资本细胞与基因产业基金的议案》。根据《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上 市公司规范运作》《公司章程》等的相关规定，本次交易在公司董事会的审批权 限下，无需提交公司股东大会审议。本次交易不构成关联交易，也不构成《上市 公司重大资产重组管理办法》规 ...

第一条 为推动重庆博腾制药科技股份有限公司（以下简称"公司"）积极履 行社会责任，规范对外捐赠行为，进一步加强捐赠事项管理，根据《中华人民共和 国公益事业捐赠法》《中华人民共和国公司法》《深圳证券交易所上市公司自律监 管指引第 2 号—创业板上市公司规范运作》等法律、法规以及《重庆博腾制药科技 股份有限公司章程》（以下简称"《公司章程》"）等有关规定，结合公司实际情 况，制定本制度。 第二条 本制度适用于公司及下属全资子公司、控股子公司（以下简称"子公 司"）。未经授权，公司下属子公司不得开展对外捐赠事项。 第三条 本制度所称"对外捐赠"，是指公司及子公司以公司或以子公司的名义自 愿无偿将其有权处分的合法财产赠送给合法的受赠人，用于与生产经营活动没有直接 关系的公益事业的行为。 重庆博腾制药科技股份有限公司 对外捐赠管理制度 （二零二五年二月） 第一章 总 则 第二章 对外捐赠的原则 （二）救济性捐赠：指向遭受自然灾害地区、事故灾难和公共卫生事件等 突发事件的捐赠，以及向定点扶贫地区或者困难的社会弱势群体和困难个人提 供的用于生产、生活救济、救助等方面的捐赠； （三）其他捐赠：指除上述捐赠以外，公司出于弘扬人 ...

重庆博腾制药科技股份有限公司（以下简称"公司"）于 2025 年 2 月 26 日 召开第五届董事会第三十次临时会议，审议通过《关于使用部分闲置自有资金进 行现金管理的议案》，为提高自有资金的使用效率，增加资金收益，实现股东利 益最大化，在保证日常经营资金需求和资金安全的前提下，公司及合并报表范围 内子公司（以下简称"子公司"）拟使用不超过人民币 20 亿元的闲置自有资金进 行现金管理，使用期限为自公司董事会决议之日起 12 个月。现将有关事项公告 如下： 一、本次使用自有资金进行现金管理的基本情况 1、投资目的 为提高自有资金的使用效率，在保证日常经营资金需求和资金安全的前提下， 公司及子公司拟使用部分闲置自有资金进行现金管理，以增加资金收益，为公司 及股东获取更好的回报。 2、投资品种 股票代码：300363 股票简称：博腾股份 公告编号：2025-005 号 重庆博腾制药科技股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 公司将按照相关规定严格控制风险，对投资产品进行严格评估筛选，选择银 行、证券公 ...

Financial Performance - The company expects a net profit attributable to shareholders to be a loss of between 230 million to 290 million yuan, compared to a profit of 266.86 million yuan in the same period last year [4]. - The expected operating revenue for 2024 is between 2.9 billion to 3.06 billion yuan, representing a year-on-year decline of approximately 17% to 21% [6]. - The company reported a non-recurring loss impact of approximately 3.28 million yuan for 2024, compared to a gain of 20.52 million yuan in 2023 [4]. Revenue Expectations - Excluding the impact of significant orders, the company anticipates a year-on-year revenue growth of 10% to 16% [7]. Operational Challenges - The decline in profit is attributed to insufficient capacity utilization, increased fixed cost allocation, and high operational expenses due to expanded operational scale [7]. - The company plans to make impairment provisions for assets that may show signs of impairment based on prudence [7]. Financial Reporting - The financial data presented is preliminary and has not been audited by registered accountants, with detailed financial data to be disclosed in the 2024 annual report [8].

北京市万商天勤律师事务所 关于重庆博腾制药科技股份有限公司 2024 年第一次临时股东大会的 法律意见书 1 北京市万商天勤律师事务所（以下简称"本所"）接受重庆博腾制药科技股 份有限公司（以下简称"公司"）的委托，指派律师出席了公司召开的 2024 年 第一次临时股东大会。根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东大会规则》（下称"《股东大会规则》"）等法律、法规和规范性 文件以及《重庆博腾制药科技股份有限公司章程》（下称"《公司章程》"）的要 求，就公司 2024 年第一次临时股东大会（下称"本次股东大会"）的相关事宜 出具本法律意见书。 公司已向本所律师提供了本所律师认为出具本法律意见书必要的文件资料， 本所律师对该等文件和资料进行了核查、验证，并据此出具法律意见。 本所律师仅就本次股东大会的召集、召开程序、出席会议人员资格、召集 人资格及会议表决程序、表决结果是否符合《公司法》《股东大会规则》以及 《公司章程》发表意见。 本所律师同意公司将本法律意见书作为本次股东大会公告的必备文件，随 其他公告文件一起公告。 本所律师根据《股东大会规则》的要求，按照律师行业公认的业务标准、 ...